AUS
NZ
UK
CA
USA
IND
Highlights
- IDEAYA secures exclusive global license for SHR-4849, a promising ADC targeting Small Cell Lung Cancer (SCLC).
- $75M upfront payment with potential for up to $1.045B in milestone payments and royalties.
- Phase 1 trial shows strong early efficacy with a ~73% response rate in SCLC patients.
IDEAYA Biosciences (NASDAQ:IDYA), a biotechnology company focused on developing targeted cancer therapies, has announced that it has secured an exclusive global license outside Greater China for SHR-4849, a Phase 1 DLL3-targeting antibody-drug conjugate (ADC) from Hengrui Pharma. SHR-4849 is being investigated for the treatment of Small Cell Lung Cancer (SCLC) and Neuroendocrine Tumors (NETs), both of which have significant unmet medical needs. Early clinical results for SHR-4849 are promising, particularly in SCLC, where the therapy has shown a remarkable ~73% response rate at therapeutic doses.
Under the terms of the agreement, IDEAYA will receive a $75 million upfront payment and is eligible for additional milestone payments totaling up to $1.045 billion, along with royalties on future sales. The deal provides IDEAYA with the financial resources needed to continue advancing its pipeline, including the planned filing of a U.S. Investigational New Drug (IND) application for SHR-4849 in the first half of 2025. The deal structure also ensures that IDEAYA’s cash runway is extended through at least 2028, providing the company with the financial stability to focus on its clinical development programs.
SHR-4849 has demonstrated encouraging early clinical efficacy in an ongoing Phase 1 trial, with a ~73% response rate in SCLC patients at therapeutic doses. In this trial, 8 out of 11 evaluable SCLC subjects achieved partial responses, suggesting that the drug may be highly effective in treating this difficult-to-treat cancer. Moreover, SHR-4849 has exhibited a manageable safety profile, with most adverse events classified as Grade 1 or 2. This is a positive indicator that the drug may be well tolerated by patients, which is crucial for its potential to become a viable treatment option.
The potential market for SHR-4849 is substantial. DLL3, the target of the drug, is expressed in approximately 85% of SCLC cases and 20-40% of NET cases, providing a large patient population for whom effective treatments are currently lacking. If SHR-4849 continues to show positive results in ongoing clinical trials, it could address significant unmet needs in both SCLC and NETs, two cancers with poor prognosis and limited treatment options.
However, while the early data is promising, there are still uncertainties. The Phase 1 trial is ongoing, and the maximum tolerated dose has not yet been determined. Additionally, the U.S. IND filing for SHR-4849 is not expected until the first half of 2025, which means the company’s ability to advance the drug into later-stage trials may take additional time. The upfront cash payment of $75 million also represents a significant commitment for IDEAYA, which could strain its financial resources if milestone payments are not met as expected.
